Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose: The study null hypothesis is that vitamin D supplementation will not influence time to acute respiratory tract infection in sheltered accommodation residents.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Vitamin D Supplementation in Chronic Obstructive Pulmonary Disease

NCT00977873

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2/PHASE3

Cholecalciferol Intervention to Prevent Respiratory Infections Study

NCT01549938

Respiratory Tract Infection Vitamin D Deficiency

COMPLETED PHASE2

Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml

NCT04810949

Covid19 Influenza A Influenza B +1 more

TERMINATED NA

Vitamin D and the Influenza Epidemic

NCT01182870

Influenza

COMPLETED PHASE3

Vitamin D for COVID-19 Trial

NCT04536298

COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population will comprise sheltered accommodation residents and staff fulfilling eligibility criteria. Half of the sheltered accommodation schemes will be randomly allocated to 2-monthly oral bolus vitamin D supplementation (Vigantol oil) over a period of one year, and half to placebo.

Participants will be followed for one year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Tract Infections Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Miglyol oil

Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year

Group Type PLACEBO_COMPARATOR

Miglyol oil

Intervention Type DIETARY_SUPPLEMENT

Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year

Vigantol oil

Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year

Group Type ACTIVE_COMPARATOR

Cholecalciferol (Vitamin D/Vigantol oil)

Intervention Type DIETARY_SUPPLEMENT

Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cholecalciferol (Vitamin D/Vigantol oil)

Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year

Intervention Type DIETARY_SUPPLEMENT

Miglyol oil

Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vigantol oil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Permanent resident or member of staff at sheltered accommodation unit
* If a woman of child-bearing potential, is sexually abstinent or has negative pregnancy test within 7 days of recruitment and agrees to use reliable form of contraception until she has completed the study
* Able to give written informed consent to participate
* Age ≥ 16 years on day of first dose of IMP

Exclusion Criteria

* Current diagnosis of asthma or chronic obstructive pulmonary disease
* Chronic upper or lower respiratory infection or other condition causing chronic cough
* Condition requiring treatment with vitamin D at a dose of \> 10 micrograms vitamin D/day
* Episode of upper or lower respiratory tract infection up to 28 days before first dose of IMP
* Known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure, terminal illness, lymphoma or other malignancy not in remission at time of recruitment
* Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, phenytoin, primidone or long-term immunosuppressant therapy
* Taking oral preparation containing \> 10 micrograms vitamin D/day up to 2 months before first dose of IMP
* Using topical vitamin D analogue
* Treatment with any investigational medical product or device up to 4 months before first dose of IMP
* Breastfeeding, pregnant or planning a pregnancy
* Baseline corrected serum calcium \> 2.65 mmol/L
* Baseline serum creatinine \> 125 micromol/L
* Inability to complete symptom diary with / without assistance
* Cognitive impairment or communication problem precluding informed consent or successful completion of study evaluations

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes